Kidney Cancer CLEAR Trial biomarker analysis: Toni Choueiri MD | Dana-Farber Cancer Institute
Follow
Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a firstline therapy in patients diagnosed with advanced kidney cancer. DanaFarber's Toni Choueiri, MD, presents at #ASCO24. Video published 6/7/2024